a Department of Pharmaceutical Chemistry, Faculty of Pharmacy , Istanbul University , Istanbul , Turkey.
b Department of NEUROFARBA , Sezione di Scienze Farmaceutiche Universita degli Studi di Firenze , Sesto Fiorentino , Florence , Italy.
J Enzyme Inhib Med Chem. 2018 Dec;33(1):1299-1308. doi: 10.1080/14756366.2018.1499628.
A small collection of 26 structurally novel thiazolidinone-containing compounds, without the well-known sulphonamide zinc-binding group, were synthesised and tested in enzyme inhibition assays against the tumour-associated hCA IX enzyme. Inhibition constants in the lower micromolar region (K < 25 μM) have been measured for 17 of the 26 compounds. Even though the K values are relatively weak, the fact that they do not contain a sulphonamide moiety suggests that these compounds do not interact with the active site zinc ion. Therefore, docking studies and molecular dynamics simulations have been performed to suggest binding poses for these structurally novel inhibitors.
合成并测试了一小部分 26 种结构新颖的含噻唑烷酮的化合物,这些化合物不含众所周知的磺酰胺锌结合基团,然后在酶抑制试验中针对肿瘤相关的 hCA IX 酶进行了测试。26 种化合物中有 17 种的抑制常数在较低的微摩尔范围内(K < 25 μM)。尽管 K 值相对较弱,但这些化合物不含磺酰胺部分,这表明它们不会与活性位点的锌离子相互作用。因此,进行了对接研究和分子动力学模拟,以提出这些结构新颖的抑制剂的结合构象。